PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. 21/03/2025			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

30/24/30	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/24/30	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	1.68TCr 1.21Cr 1.04Cr 97.37L 89.02L 1.68Cr 116.29Cr 1.7Cr 12Cr 4.48Cr 58Cr 4.56Cr 4.46Cr 193.2Cr	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	2.38TCr 1.72Cr 1.48Cr 1.38Cr 1.26Cr 2.38Cr 164.94Cr 2.41Cr 16Cr 6.35Cr 83Cr 6.47Cr 6.33Cr 274.03Cr	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

30/24/30	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
30/24/30	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
22/24/22	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
25/24/25	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
21/24/21	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
16/24/16	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
26/23/26	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
21/23/21	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
15/23/15	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
31/23/31	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
31/23/31	PCL to Raise 36 Billion Won via Share Issuance	MT
23/23/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
29/22/29	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	3,40,000
10 years	5,900	5,23,333.33

PCL, Inc. Share Price

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	28/03/2024
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	28/03/2024

Director	Title	Age	Since
So-Yeon Kim BRD	Director/Board Member	55	-
Chul-Joon Kim BRD	Director/Board Member	73	-
Mu-Yong So BRD	Director/Board Member	53	28/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-85.82%	1.21Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-1.69%	+3.15%	+96.54%	+320.92%	414.79Cr
IOVANCE BIOTHERAPEUTICS, INC.	-2.77%	+13.52%	+199.63%	+32.57%	375.51Cr
VERACYTE, INC.	-1.99%	-1.45%	+33.77%	+65.15%	340.13Cr
CAREDX, INC.	-2.28%	+2.41%	+266.23%	+445.35%	251.48Cr
BGI GENOMICS CO., LTD.	-0.71%	+3.10%	-21.61%	-20.34%	240.96Cr
FREENOME, INC.	-0.22%	+6.00%	+30.37%	-	148.38Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	-2.43%	+48.42%	+244.08%	-16.70%	128.73Cr
SEEGENE, INC.	+5.41%	0.00%	+22.94%	+49.53%	100.26Cr
HANGZHOU ALLTEST BIOTECH CO., LTD.	-0.67%	-3.47%	-36.72%	+1.04%	55Cr
Average	-0.90%	+9.58%	+83.52%	+87.97%	205.67Cr
Weighted average by Cap.	-1.46%	+10.25%	+109.13%	+145.35%

	2023	2024
Net sales	842.95Cr 60.92L 52.21L 48.84L 44.66L 84.27L 58Cr 85.17L 5.78Cr 2.25Cr 29Cr 2.29Cr 2.24Cr 97Cr	124.62Cr 9L 8L 7L 7L 12.46L 8.62Cr 12.59L 85.45L 33.22L 4.33Cr 33.82L 33.08L 14Cr
Net income	-2.03TCr -1.47Cr -1.26Cr -1.18Cr -1.08Cr -2.03Cr -140.61Cr -2.05Cr -14Cr -5.42Cr -71Cr -5.51Cr -5.39Cr -233.61Cr	-5.23TCr -3.78Cr -3.24Cr -3.03Cr -2.77Cr -5.23Cr -362.21Cr -5.29Cr -36Cr -14Cr -181.88Cr -14Cr -14Cr -601.77Cr
Net Debt	720.41Cr 52.07L 44.62L 41.74L 38.16L 72.02L 50Cr 72.78L 4.94Cr 1.92Cr 25Cr 1.95Cr 1.91Cr 83Cr	703.02Cr 50.81L 43.54L 40.74L 37.24L 70.28L 49Cr 71.03L 4.82Cr 1.87Cr 24Cr 1.91Cr 1.87Cr 81Cr